12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bexsero regulatory update

Novartis said Health Canada approved Bexsero to vaccinate against meningococcal disease caused by Neisseria meningitides serogroup B in patients ages 2 months through 17 years. Novartis plans to launch the...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >